Kangzhe Pharmaceutical: Signs cooperation agreement with Zhixiang Jintai

Kangzhe Pharmaceutical announced that its subsidiary has signed a cooperation agreement with Chinese biopharmaceutical company Zhixiang Jintai, obtaining the exclusive commercialization rights of Vectibix monoclonal antibody injection and Soluvimab monoclonal antibody injection in mainland China, as well as exclusive licensing rights in the Asia-Pacific region and the Middle East and North Africa. Vectibix monoclonal antibody injection is used for the treatment of tetanus, and Soluvimab monoclonal antibody injection is used for the treatment of rabies.